Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 9.5%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s stock price traded up 9.5% during mid-day trading on Thursday . The company traded as high as $2.71 and last traded at $2.41, 73,219 shares traded hands during trading. A decline of 93% from the average session volume of 1,050,120 shares. The stock had previously closed at $2.20.

A number of research analysts have recently issued reports on the company. Stifel Nicolaus downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the company from $10.00 to $4.00 in a report on Monday, July 29th. BidaskClub downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 19th. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 3rd. Gabelli raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Wednesday. Finally, ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $6.70.

The stock has a market capitalization of $150.91 million, a P/E ratio of -2.12 and a beta of 0.75. The business has a fifty day moving average price of $1.81 and a 200-day moving average price of $5.02.



Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.13). The firm had revenue of $9.68 million during the quarter, compared to analysts’ expectations of $28.52 million. Lexicon Pharmaceuticals’s quarterly revenue was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.33) earnings per share. As a group, research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.8 earnings per share for the current year.

In other news, insider Lonnel Coats bought 40,000 shares of the stock in a transaction on Monday, August 19th. The shares were bought at an average price of $1.35 per share, with a total value of $54,000.00. Following the completion of the acquisition, the insider now owns 87,695 shares in the company, valued at $118,388.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sam L. Barker bought 24,000 shares of the stock in a transaction on Friday, August 2nd. The stock was purchased at an average cost of $1.18 per share, for a total transaction of $28,320.00. Following the acquisition, the director now owns 40,187 shares of the company’s stock, valued at approximately $47,420.66. The disclosure for this purchase can be found here. In the last three months, insiders acquired 111,000 shares of company stock worth $143,670. 6.40% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Lexicon Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after acquiring an additional 319,382 shares during the period. First Manhattan Co. lifted its holdings in Lexicon Pharmaceuticals by 7.3% in the second quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock valued at $18,555,000 after acquiring an additional 201,393 shares during the period. Clearbridge Investments LLC increased its position in Lexicon Pharmaceuticals by 3.4% in the first quarter. Clearbridge Investments LLC now owns 1,292,130 shares of the biopharmaceutical company’s stock worth $7,184,000 after buying an additional 42,540 shares in the last quarter. Pictet Asset Management Ltd. increased its position in Lexicon Pharmaceuticals by 13.4% in the second quarter. Pictet Asset Management Ltd. now owns 665,776 shares of the biopharmaceutical company’s stock worth $4,188,000 after buying an additional 78,926 shares in the last quarter. Finally, Pinnacle Associates Ltd. increased its position in Lexicon Pharmaceuticals by 1.8% in the first quarter. Pinnacle Associates Ltd. now owns 550,549 shares of the biopharmaceutical company’s stock worth $3,061,000 after buying an additional 9,615 shares in the last quarter. 98.88% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: Hedge Funds – Risk or Reward?

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.